Neurological disorders have been pinpointed by WHO as one of the greatest threats to public health. As an example, nearly 10 million people develop dementia each year and the number of people living with dementia is expected to triple from 50 million to 152 million by 2050. Today, the annual global cost for dementia is estimated to US$ 818 billion, corresponding to more than 1% of global GDP.
Researcher and pharma companies all over the world are mapping the biological processes that causes various types of brain disorders with the mission to develop new drugs and treatments. Recent breakthroughs in the gene sequencing technology has enabled researchers to classify single cells in tissue samples based on their gene expression. In this process, the cells are isolated from their tissue of origin – they are taken out of context and the location of the cell types in the brain tissue remains unknown.
As a result of more than 10 years research, the company Cartana has developed a technology that enables gene sequencing directly on full tissue samples. The technology gives researchers information on both the type and function of single brain cells and their location in relation to each other, revolutionizing the possibilities to research the brain’s normal function as well as its disorders and new therapies.
The global market for classification of cells based on their gene expression (i.e. single cell analysis) was valued to 1.67 billion USD in 2017 and is expected to grow to 3.6 billion USD by 2022. Cartana launches its first product on this billion-dollar market with the target to significantly improve the condition for research on brain disorders and new drugs.
Opportunity to join Cartana’s expansion!
Become a member to receive information about the company before everyone else and invitations to investor lunches with the company’s CEO Malte Kühnemund.
More from Sciety
Sciety is an investment network that wants innovations that make a difference to reach their full potential and create value. We select unlisted growth companies within life science and prepare them for investments from our members.
Would you like to receive news about the sector and invitations to upcoming investor presentations directly in your inbox? Subscribe for our newsletter